Unlocking the Therapeutic Potential of Nucleotides for Rare Diseases
We are harnessing Nucleotide-Based Therapies to Rewrite the Future of Rare Diseases.
From molecular insight to life-changing treatments, our team focuses on the power of nucleotides to address unmet medical needs.
Launched in Lausanne in 2019, Nuvamid is a clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare diseases.
Nuvamid’s Swiss team has developped a unique expertise with endogenous molecules to offer breakthrough therapeutics for the treatment of rare blood diseases.
In cooperation with leading partners and institutions in Switzerland (Lausanne University), France (EFS, INSERM, CNRS), and the USA (Buck Institute), Nuvamid has aquired a unique knowledge in blood cells disorders. Our lead molecule NUV01, is currently evaluated in three Phase 2 trials.
In addition to its efficacy, NUV01 is considered extremely safe. We believe that our novel approach could bring a revolutionary treatment to rare blood diseases.